menu ☰
menu ˟

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

Creator:

Parravano, M., Menchini, F. and Virgili, G.

Subject Keywords: Diabetic macular oedema (DMO), Diabetic retinopathy, Vision, Therapy
Set: Chronic Conditions
Conditions
Diabetes
Type: Article
Region: International (other)
Description:

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. The retina at the macula thickens and this can cause gradual loss of central vision. Although grid or focal laser photocoagulation has been shown to reduce the risk of visual loss in DMO or clinically significant macular oedema (CSMO), vision is rarely improved. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) modalities has recently been proposed for improving vision in people with DMO. Anti-VEGF drugs are delivered by an injection in the vitreous cavity of the eye.This review aims to assess the effectiveness of anti-VEGF therapy for preserving or improving vision in people with DMO.

Date:

07/10/2009

Rights: © The Cochrane Collaboration
Suggested citation:

Parravano, M., Menchini, F. and Virgili, G.. (2009) Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema [Online]. Available from: http://www.thehealthwell.info/node/95976 [Accessed: 24th September 2017].

  

View your saved citations and reading lists

Contributor:

Other partner websites
 
Click here to view all the resources gathered from this organisation's website.